Evidence map›Paper›PMID 29094037›Full record

ArticleFrontiers in chemistry2017

Solid-Phase Synthesis of Difficult Purine-Rich PNAs through Selective Hmb Incorporation: Application to the Total Synthesis of Cell Penetrating Peptide-PNAs.

Julien Tailhades, Hotake Takizawa, Michael J Gait, Don A Wellings, John D Wade, Yoshitsugu Aoki, Fazel Shabanpoor

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Backbone Protecting Groups for Enhanced Peptide and Protein Synthesis.Angewandte Chemie (International ed. in English) · 2025
    Review
  2. The Assembly of Fluorescently Labeled Peptide-Oligonucleotide Conjugates.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Julien TailhadesThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Hotake TakizawaDepartment of Molecular Therapy, National Center of Neurology and Psychiatry, Tokyo, Japan.
Michael J GaitLaboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom.
Don A WellingsSpheriTech Ltd., Runcorn, United Kingdom.
John D WadeThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Yoshitsugu AokiDepartment of Molecular Therapy, National Center of Neurology and Psychiatry, Tokyo, Japan.
Fazel ShabanpoorThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
University of Melbourne · AUNational Center of Neurology and Psychiatry · JPMedical Research Council · GBSpheriTech (United Kingdom) · GB

Funding

Medical Research Council MC_U105178803Medical Research Council U105178803
6 · The paper itself

Abstract

Antisense oligonucleotide (ASO)-based drug development is gaining significant momentum following the recent FDA approval of Eteplirsen (an ASO based on phosphorodiamidate morpholino) and Spinraza (2'-

Indexed as

cell penetrating peptideduchenne muscular dystrophyHmb incorporationpeptide nucleic acidPNA conjugation

Identifiers

PMID29094037
PMCPMC5651559
OpenAlexW2766880959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.